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Abstract
Background: S100A7 is a calcium-binding protein with chemotactic and antimicrobial properties.
S100A7 protein levels are decreased in nasal lavage fluid from individuals with ongoing allergic
rhinitis, suggesting a role for S100A7 in allergic airway inflammation. The aims of this study were
to describe genetic variation in S100A7 and search for associations between this variation and
allergic rhinitis.
Methods: Peripheral blood was collected from 184 atopic patients with a history of pollen-induced
allergic rhinitis and 378 non-atopic individuals, all of Swedish origin. DNA was extracted and the
S100A7  gene was resequenced in a subset of 47 randomly selected atopic individuals. Nine
polymorphisms were genotyped in 184 atopic and 378 non-atopic individuals and subsequently
investigated for associations with allergic rhinitis as well as skin prick test results. Haplotypes were
estimated and compared in the two groups.
Results:  Thirteen polymorphisms were identified in S100A7, of which 7 were previously
undescribed. rs3014837 (G/C), which gives rise to an Asp → Glu amino acid shift, had significantly
increased minor allele frequency in atopic individuals. The major haplotype, containing the major
allele at all sites, was more common in non-atopic individuals, while the haplotype containing the
minor allele at rs3014837 was equally more common among the atopic individuals. Additionally,
heterozygotes at this site had significantly higher scores in skin prick tests for 9 out of 11 tested
allergens, compared to homozygotes.
Conclusion: This is the first study describing genetic variation, associated with allergy, in S100A7.
The results indicate that rs3014837 is linked to allergic rhinitis in our Swedish population and
render S100A7 a strong candidate for further investigations regarding its role in allergic
inflammation.
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Introduction
The upper airways are relatively easy to access and offer
the opportunity for allergen provocation, in conjunction
with repeated sampling and measurements, with a mini-
mum of discomfort and risk for the patient [1,2]. This has
prompted us to use allergic rhinitis as an experimental
model when searching for suitable mediators to target in
allergic airway inflammation. Using 2-dimensional gel
electrophoresis in combination with mass spectrometry
we have been able to identify 6 novel proteins in nasal lav-
age fluid [3]. One of these proteins, S100A7, also called
psoriasin, appeared to be of special interest since it was
found to be markedly down-regulated in patients with
symptomatic allergic rhinitis [3].
S100A7 belongs to the large family of S100 proteins,
which all have calcium-binding properties. The functions
of secreted S100A7 are poorly investigated. The idea that
S100A7 might have a role in allergic rhinitis is supported
by its potent chemotactic effects on T lymphocytes and
neutrophils [4]. Originally, S100A7 was identified in
keratinocytes from psoriatic patients, where it was found
to be highly up-regulated [5]. Thus, S100A7 was initially
thought to be a specific marker for psoriasis, thereby the
alternative name psoriasin, but it was soon found to play
a role also in atopic eczema [6,7]. The latter further cor-
roborating its newly identified involvement in allergic air-
way inflammation.
To further establish S100A7 as a factor in allergic airway
inflammation, the present study was designed to describe
the level and pattern of genetic variation in the S100A7
gene and to search for associations between this variation
and allergic rhinitis.
Methods
Subjects
Blood samples from 184 patients (80 female, 104 male)
with symptomatic birch and/or grass pollen induced aller-
gic rhinitis and 378 healthy individuals (163 female, 214
male), serving as controls. The median (range) age of
patients and controls was 32.5 (18–62) and 46 (19–69).
The diagnosis of birch and/or grass pollen induced aller-
gic rhinitis was based on a positive history of intermittent
allergic rhinitis for at least 2 years and a positive skin prick
test (SPT) or Phadiatop test (Pharmacia Upjohn, Uppsala,
Sweden) to birch and/or grass.
All patients were classified according to the ARIA criteria
[8], as having severe symptoms (itchy nose and eyes,
sneezing, nasal secretion and nasal blockage) during pol-
len season and they had all been treated with antihista-
mines and nasal steroids during pollen seasons previous
years. Controls had no history of allergic rhinitis or any
other atopic disease. Both patients and controls were of
Caucasian origin, with both parents born in Sweden. The
study was approved by the Ethics Committee of the Med-
ical Faculty, Lund University, and written informed con-
sent was obtained from all subjects.
Skin prick test
Skin prick tests (SPT) were performed with a standard
panel of 11 common airborne allergens (ALK, Copenha-
gen, Denmark) including pollen (birch, timothy, mug-
wort and ragweed), house dust mites (D. pteronyssimus
and D. farinae), molds (Cladosporium and Alternaria) and
animal allergens (cat, dog and horse). SPT were per-
formed on the volar side of the forearm with saline buffer
as negative and histamine chloride (10 mg/ml) as positive
control. All patients presented a wheal reaction diameter
>3 mm towards birch or timothy (grass) in SPT (roughly
corresponding to a 3+ or 4+ reaction when compared with
histamine [9]) or a positive Phadiatop test, with at least
class 2 in subsequent test with specific allergens. Approxi-
mately 44% of the patients were positive for birch and/or
grass only, while ~31% were positive (≥ 2) for 1–2 addi-
tional allergens, ~20% for 3–4 and ~4% for ≥ 5 additional
allergens. Controls had a negative SPT or Phadiatop test.
The score used for association analysis is defined as the
size of the wheal reaction in relation to histamine, i.e. 0–
6.
DNA sequencing
Genomic DNA was extracted from whole blood using
QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Ger-
many). A subset of 47 randomly selected individuals with
allergic rhinitis (23 female and 24 male, with median
(range) age of 35 (20–61)) were used for sequencing of
the putative promoter region, all coding regions and
flanking intronic sequences. All primer DNA sequences
are listed in Additional file 1. Samples were sequenced
using Big Dye Terminator chemistry, ver. 3.1 on an ABI
3730 sequencer (Applied Biosystems, Foster City, USA).
The sequence data was assembled and compared using
SeqScape v2.5 (Applied Biosystems). All automatically
identified candidate heterozygotes were confirmed manu-
ally and most polymorphisms were subsequently con-
firmed by independent genotyping.
Genotyping
SNP genotypes were determined using the Sequenom
MassARRAY MALDI-TOF system. The system analyzes
allele-specific primer extension products using mass-spec-
trometry. Assay design was made using the MassARRAY
Assay Design ver. 2.0 software (Sequenom Inc, USA).
Primers (Additional file 1) were obtained from Metabion
GmbH, Germany. The genotype data for rs3014837 was
also analyzed using a Taqman assay (Custom TaqMan®
SNP Genotyping Assay ID C_736084_10, Applied Biosys-
tems), on an ABI 7900 HT system. An 8-nucleotide indelRespiratory Research 2008, 9:29 http://respiratory-research.com/content/9/1/29
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was amplified using GeneAmp 9700 machines (Applied
Biosystems) and the PCR products were resolved using
capillary electrophoresis run on an ABI PRISM™ 3730
sequencer employing GeneMapper software (Applied Bio-
systems).
Genetic analysis
All polymorphisms detected by DNA sequencing were
assayed on a set of 2- and 3-generation families to check
data quality and confirm Mendelian segregation. In order
to quantify the level of genetic variation in the sequence
data we calculated the expected level of heterozygosity for
variable sites, h = 1 - p2 - q2. Where p is the allele frequency
of one of the alleles and q = 1-p. We also calculate Π which
is the average number of pairwise differences among
sequences and π which is this value per bp in the data set.
In addition, π is also the average heterozygosity (h) per
bp. Finally, we calculated K/a where K is the number of
variable sites and a = Σ1/i, i = 1..n-1 where n is the number
of investigated sequences. The rationale behind calculat-
ing K/a is the fact that if all variation in a sequence is com-
pletely neutral, then Π  =  K/a  is expected. If there is
directional or purifying selection Π  <K/a  is expected,
whereas if balancing selection is operating for two or
more alleles Π > K/a is expected.
A set of SNPs that produced good quality data were subse-
quently used to analyze 184 patients and 378 controls for
associations between genetic variation in the S100A7 gene
and allergic rhinitis. First, the genotype frequencies were
calculated and tested for Hardy-Weinberg equilibrium
(HWE). Next, alleles were investigated for associations
with allergic rhinitis using a χ2-homogeneity test. Using
the SNP data we also investigated the level and pattern of
linkage disequilibrium and haplotype frequencies. For
any two loci (sites) A and B with alleles A1/A2 and B1/B2,
respectively, linkage disequilibrium was quantified
through R2 = D2/(pA1pA2pB1pB2), where pA1 is the allele fre-
quency of allele 1 at locus A etc and D = pA1B1 - pA1pB1,
where pA1B1 is the gamete (haplotype) frequency of A1B1.
Haplotypes were estimated separately for patients and
controls using the program PHASE [10].
Results
Discovery of polymorphisms in S100A7
Sequencing of the S100A7 gene in 47 atopic individuals
resulted in identification of 13 polymorphisms, one 8-
nucleotide indel and 12 SNPs (table 1). Six of the poly-
morphisms have been previously described (rs3124216,
rs3006433, rs3014839, rs12132927, rs3014837 and
rs3014836), while the remaining 7 were previously unde-
scribed (A7:1 to A7:7). Four of the polymorphisms had
minor allele frequencies (MAFs) below 5%. The two cod-
ing polymorphisms, A7:5 (first codon position) and
rs3014837 (third codon position), are both non-synony-
mous and give rise to Lys → Gln and Asp → Glu amino
acid shifts, respectively.
Pattern of genetic variation in sequence data
As pointed out above, 2965 bp were sequenced in 47 indi-
viduals (representing 94 chromosomes) and 12 SNPs and
one indel were found. The three exons cover 439 bp and
included two of the SNPs. The expected heterozygosity (h)
for the variable sites is shown in table 1. Considering the
12 SNPs only, the sum of the h values is 1.94, which also
corresponds to Π for the 94 chromosomes. Per bp this will
be π = 1.94/2965 = 0.65 * 10-3, which is also the expected
heterozygosity per bp. Moreover, K = 12 and a = 5.126,
resulting in K/a = 2.34, i.e. K/a is only moderately larger
than Π. Thus, there is no indication that strong selection
has acted on S100A7.
Association between S100A7 polymorphisms and allergic 
rhinitis
To identify SNPs with patient-control allele differences, 8
SNPs were genotyped in 184 atopic individuals and 378
Table 1: Polymorphisms within the S100A7 locus
SNP name Alleles Contig position Location Amino acid shift Minor allele frequency Heterozygosity
A7:1 G/T 3924455 Promoter 0.08 0.14
A7:2 Indel 3924262 Promoter 0.21 0.33
rs3124216 T/A 3924209 Promoter 0.03 0.07
rs3006433 G/A 3924047 Promoter 0.15 0.25
A7:3 C/T 3923423 Intron 1 0.14 0.24
A7:4 A/T 3923336 Intron 1 0.14 0.24
rs3014839 G/A 3923095 Intron 1 0.19 0.31
rs12132927 T/C 3921916 Intron 1 0.05 0.10
A7:5 A/C 3921790 Exon 2 Lys → Gln 0.02 0.04
rs3014837 G/C 3921761 Exon 2 Asp → Glu 0.09 0.16
rs3014836 G/A 3921555 Intron 2 0.21 0.33
A7:6 C/T 3921498 Intron 2 0.01 0.02
A7:7 C/A 3921495 Intron 2 0.02 0.04Respiratory Research 2008, 9:29 http://respiratory-research.com/content/9/1/29
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controls. The allele frequencies are shown in table 2. All
investigated polymorphisms were in HWE, both in
patients and controls. For rs3014837, there was a signifi-
cant difference in MAF between atopic individuals and
controls; 0.08 and 0.05 respectively (χ2 = 5.15, p = 0.02).
Hence, the minor allele of rs3014837 is almost twice as
common in the atopic group. The analysis of this SNP was
repeated using the Taqman platform. Concordance was
found in 99.6% of the comparisons with only two out of
550 comparisons being discordant between the Taqman
and Sequenom platforms. A7:2, the 8-nucleotide indel sit-
uated in the putative promoter region, was also analyzed
for association with allergic rhinitis. There was no signifi-
cant difference in MAF between the two groups; 0.16 and
0.14, respectively (χ2 = 0.91) (table 2).
Linkage disequilibrium and haplotype frequencies
The pattern of linkage disequilibrium (LD) across S100A7
is shown in table 3. A moderately complex pattern
emerges, two SNPs, rs3006433 and rs3014839, show
almost complete LD. These two SNPs show moderately
high LD to A7:2 and rs3014837. A7:1 and A7:3 appear to
be associated, whereas A7:5 and A7:7 individually appear
to be in equilibrium with all other investigated polymor-
phisms. Given the overall distance of only 2960 bases
between A7:1 and A7:7, the level of LD is expected to be
rather high for this region. This is clearly not found in our
data.
Haplotype frequencies were estimated separately in
patients and controls (table 4). Two haplotypes stand out
as differing in frequency between the two groups. One is
Table 2: Allele frequencies for selected polymorphisms in S100A7
SNP name Controls Patients Association test, χ2-value (p-value)
Allele frequency % HWE χ2value Allele frequency % HWE χ2-value
A7:1 G 97.5 0.25 G 95.6 1.32 2.79 (0.09)
T2 . 5 T4 . 4
A7:2 I 85.8 0.02 I 84.2 1.20 0.91 (0.34)
D 14.2 D 15.8
rs3006433 C 87.5 1.09 C 84.9 1.26 1.44 (0.23)
T 12.5 T 15.1
A7:3 C 90.1 1.70 C 89.9 0.01 0.01 (0.93)
T9 . 9 T 1 0 . 1
rs3014839 C 87.5 1.00 C 85.1 1.20 1.28 (0.26)
T 12.5 T 14.9
rs12132927 T 91.6 1.20 T 90.4 0.33 0.45 (0.50)
C8 . 4 C9 . 6
A7:5 A 99.1 0.03 A 98.6 0.04 0.45 (0.50)
C0 . 9 C1 . 4
rs3014837 G 95.2 1.68 G 91.8 0.59 5.15 (0.02)
C4 . 8 C8 . 2
A7:7 C 98.8 0.06 C 99.2 0.01 0.33 (0.57)
A1 . 2 A0 . 8
I = insertion, D = deletion
SNP with significant association test result (p < 0.05) is in bold.
Table 3: LD pattern across the S100A7 gene
A7:1 A7:2 rs3006433 A7:3 rs3014839 rs12132927 A7:5 rs3014837 A7:7
A7:1
A7:2 0.006
rs3006433 0.005 0.574
A7:3 0.290 0.016 0.017
rs3014839 0.005 0.574 0.992 0.017
rs12132927 0.003 0.012 0.015 0.008 0.012
A7:5 0.000 0.005 0.007 0.001 0.007 0.001
rs3014837 0.002 0.224 0.377 0.007 0.378 0.006 0.011
A7:7 0.000 0.002 0.002 0.000 0.002 0.001 0.004 0.001
Moderate to high LD-values (R2) are in bold.Respiratory Research 2008, 9:29 http://respiratory-research.com/content/9/1/29
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the haplotype which carries the major allele in all sites ('1'
in table 4), which is more common in controls. This is
also by far the most common single haplotype. The other
is haplotype no '5' in table 4 which is equally more com-
mon among the patients. This haplotype has two interest-
ing features: 1) The minor allele at rs3014837 is almost
completely associated to this haplotype, i.e. the allele fre-
quency difference at rs3014837 observed above is at the
same time a haplotype frequency difference. 2) Haplotype
no. '5' carries four minor alleles which is the highest
number of minor alleles of any haplotype appearing in
the analysis.
Association between genotype in patients and SPT results
The Kruskall-Wallis non-parametric test was used to test
for effect of genotype on the level of allergy, as scored in
skin prick test, among the patients. All combinations of
polymorphisms and allergens were tested, which means
that a total of 99 tests were performed of which six tests
yielded a p-value below 0.05. Under an overall null-
hypothesis of no effects, this is the approximate number
of tests expected to show a p-value below 0.05. However,
four of the p-values are less than one percent. Using a
Poisson approximation, the probability to obtain four or
more p-values < 0.01 is less than two percent. Thus, our
conclusion is that the overall null-hypothesis of no effects
of any polymorphism can be rejected. The lowest p-value
is obtained for the combination rs3014837 * "Alternaria",
which is interesting since rs3014837 was also found to
have the largest difference in allele frequency between
patients and controls.
The genotype distribution at rs3014837 among patients
that were given a SPT score for "Alternaria" was 91 GG, 18
GC and 2 CC, i.e. a highly skewed distribution. Thus, the
relevant difference is that between GG and GC individu-
als. It is then noteworthy that the heterozygotes, which are
overrepresented among the atopic individuals, also have a
higher average score for "Alternaria" among the atopic
individuals. When the genotypic means of rs3014837 for
all allergens are compared, it is found that GC individuals
have a higher mean than GG individuals in 9 out of 11
cases. This corresponds to a p-value of 0.033 in a one-
sided sign-test, and further strengthens the hypothesis
that genetic variation in S100A7 is related to allergic rhin-
itis.
Discussion
The present study has revealed a SNP (rs3014837) that is
associated with the occurrence of allergic rhinitis. When
comparing 184 atopic with 378 control individuals a sig-
nificant allele frequency difference was detected (0.08 ver-
sus 0.05, χ2 = 5.15, p = 0.02). The minor allele is more
common in the atopic group and is to a major part present
on one specific haplotype, i.e. the allele frequency differ-
ence is at the same time a haplotype frequency difference.
The association is corroborated by the fact that the SPT
scores are significantly higher for heterozygotes compared
to homozygotes at this locus for 9 out of 11 allergens
tested. It should be emphasized that although there was a
10 year age difference between patients and healthy con-
trols this does not seem to affect the outcome in the asso-
ciation test. We have done this test when the material was
matched according to age and gender as well, with similar
results (data not shown). Due to the power reduction
appearing when using the matched material we have cho-
sen to use the original population.
It is well known that the development of allergic disease is
a complex process, influenced by interactions between
numerous environmental and genetic factors [11].
Although genetic predisposition clearly is involved, the
Table 4: Estimated haplotype frequencies in patients and controls
SNP A7:1 A7:2† rs3006433 A7:3 rs3014839 rs12132927 rs3014837 A7:7 Frequency (%)
Haplotype* Controls Patients Difference
1 G I C C C T G C 63.5 60.1 3.4
2 G I CCC C G C 8.1 9.5 -1.4
3G I C T C T G C 7.2 5.7 1.5
4G DTC T TG C 6 . 6 5 . 5 1 . 1
5G DTC T T C C 3.6 7.1 -3.5
6G D CCC T GC 3 . 43 . 0 0 . 4
7 T IC T C T G C 2.5 4.4 -1.9
8 G I CCC T GA 1.2 0.8 0.4
9G I T C T T G C 1.2 1.6 -0.4
10 G I T C T T C C1 . 0 0 . 6 0 . 4
* Only haplotypes estimated to be present in at least one individual are listed. This corresponds to 98.3% of all haplotypes present in both patients 
and controls. A7:5 is not included since it was estimated by PHASE to appear only on haplotypes with lower frequencies. Minor alleles are in bold.
† I = insertion, D = deletionRespiratory Research 2008, 9:29 http://respiratory-research.com/content/9/1/29
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nature of this predisposition is still debated. No single
gene has been found responsible for the development of
allergic disease, thus interaction between several different
genes, each with little to modest effect, is more likely. A
number of genes with association to allergic disease have
been reported [12,13]. The majority of studies are how-
ever for asthma phenotypes. In 2006, Ober and Hoffjan
presented a list of 118 genes that had been associated with
asthma or atopy-related traits. However, only 23 genes
had been investigated for association with the phenotype
allergic rhinitis [13].
The S100A7 gene is located on chromosome 1q21 [14],
within a cluster of genes belonging to the S100 gene fam-
ily [15]. This gene family consists of approximately 24
genes, of which 18 are situated on chromosome 1q21
[16]. The genomic organization of S100A7 was character-
ized by Semprini et al. in 1999 [17]. The gene is 2.7 kb
large and consists of three exons and two introns. The first
exon is untranslated, while exons two and three are cod-
ing for the N- and C-terminal EF-hands, respectively. In
addition, a 744-bp promoter sequence is located in the 5'-
UTR region [17].
A total of 13 polymorphisms were identified in S100A7, 7
of which have previously not been described. The gene
was resequenced in 47 individuals, which means that the
detection rate for SNPs with a minor allele frequency of ≥
5% is approximately 0.99, and the corresponding number
for SNPs with a minor allele frequency of 1% is 0.87 [18].
Hence, we have described a major part of the genetic var-
iation for S100A7 in our population. The level of LD that
is observed in S100A7 is clearly lower than what is gener-
ally observed in the HapMap data within such a limited
part of the genome. The LD pattern of a region is influ-
enced by a number of factors, one important determinant
being the amount of recombination per physical unit.
One possibility is thus that S100A7 is situated in a region
with a high level of recombination. Comparing with Hap-
Map data we see that S100A7 is located in a gene-rich
region with recombinational hotspots fairly close on both
sides. The observed level of LD is fairly low confirming
our results in this respect. In addition, the rs3014837 SNP
is detected exclusively in the European and not in the
Yoruban, Chinese or Japanese population samples of the
HapMap project. Comparing this position in the human
genome with the corresponding position in the genome
of our closest relative, the chimpanzee (Pan troglodytes),
we found that the common allele was G in both species.
The same was true for the rhesus monkey (Macaca
mulatta). Thus, the G allele is most likely the ancient allele
being present in our monkey relatives and the disease-
associated C allele may have arisen in the European pop-
ulation.
The rs3014837 SNP gives rise to an Asp → Glu shift at
amino acid position 28. This SNP is located in exon 2 and
is coding for the N-terminal EF-hand. In contrast to most
of the other S100 proteins, S100A7 is not able to bind cal-
cium in this EF-hand [19]. The structure of S100A7 con-
tains five α helices which have been named I-IV + II'. The
N-terminal EF-hand is made up by helix I and II [19].
Amino acid 28 is positioned right before the first amino
acid of helix II and this amino acid is a conserved lysine
that has been reported to be critical for calcium-binding
[20]. Amino acid shifts in this region might give rise to
functional changes that can affect the ability to bind cal-
cium. However, since rs3014837 gives rise to a shift
between aspartic and glutamic acid, which both are acidic
amino acids, this can not be considered a dramatic
change, and consequently it is difficult to predict the func-
tional effects of this SNP. Functional studies are necessary
to answer this question.
Although allergic rhinitis primarily affects the upper air-
ways, it also has systemic manifestations, and it is well
known that allergic rhinitis is closely related to asthma
[21,22]. Thus, these two atopic phenotypes probably
share some of their genetic background. However, only 17
of the genes listed in [13] were found to be associated with
the rhinitis phenotype. Very few of these studies have
been replicated in other populations and may therefore to
some extent be spurious findings. The lack of replication
is true also in our study. Nevertheless, the altered levels of
S100A7 detected in patients with allergic rhinitis and
atopic eczema, respectively, suggest that S100A7 is
involved in allergic inflammation and in the current study
we have found a SNP that gives rise to an Asp → Glu
amino acid shift that is associated with allergic rhinitis.
Conclusion
The S100A7 protein has previously been suggested to play
a role both in innate immunity and in allergic inflamma-
tion [6,7,23] and we have detected marked differences in
the levels of this protein in nasal lavage fluid from
patients compared to controls [3]. The findings in the
present study indicate that certain genetic variation in this
gene is influencing the occurrence of allergic rhinitis. Alto-
gether, this renders the S100A7 protein a good candidate
for further studies in relation to allergic inflammation.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
MB and CH coordinated the study. TS performed the
majority of genetic analyses. All authors participated in
the design, interpretation of data, drafting of the manu-
script and they have all approved the final text.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Respiratory Research 2008, 9:29 http://respiratory-research.com/content/9/1/29
Page 7 of 7
(page number not for citation purposes)
Additional material
Acknowledgements
This work was supported by the Swedish Medical Research Council, the 
Swedish Heart Lung Foundation, the Swedish Association for Allergology 
and the Swedish Foundation for Health Care Science and Allergic Research. 
The authors would also like to thank Ingegerd Larsson, Ann Reutherborg, 
Anna Karin Bastos, Josefine P. Riikonen and Eva Thylander for generous 
help with collecting the blood samples, and Agneta Östensson, Agneta 
Sterner, Liselotte Hall and Maria Sterner for DNA sequencing and SNP gen-
otyping.
References
1. Hansel TT, Erin EM, Barnes PJ: The allergen challenge.  Clin Exp
Allergy 2002, 32(2):162-167.
2. Benson M, Fransson M, Martinsson T, Naluai AT, Uddman R, Cardell
LO: Inverse relation between nasal fluid Clara Cell Protein 16
levels and symptoms and signs of rhinitis in allergen-chal-
lenged patients with intermittent allergic rhinitis.  Allergy
2007, 62(2):178-183.
3. Bryborn M, Adner M, Cardell LO: Psoriasin, one of several new
proteins identified in nasal lavage fluid from allergic and non-
allergic individuals using 2-dimensional gel electrophoresis
and mass spectrometry.  Respir Res 2005, 6:118.
4. Jinquan T, Vorum H, Larsen CG, Madsen P, Rasmussen HH, Gesser
B, Etzerodt M, Honore B, Celis JE, Thestrup-Pedersen K: Psoriasin:
a novel chemotactic protein.  J Invest Dermatol 1996, 107(1):5-10.
5. Madsen P, Rasmussen HH, Leffers H, Honore B, Dejgaard K, Olsen E,
Kiil J, Walbum E, Andersen AH, Basse B, et al.: Molecular cloning,
occurrence, and expression of a novel partially secreted pro-
tein "psoriasin" that is highly up-regulated in psoriatic skin.  J
Invest Dermatol 1991, 97(4):701-712.
6. Algermissen B, Sitzmann J, LeMotte P, Czarnetzki B: Differential
expression of CRABP II, psoriasin and cytokeratin 1 mRNA
in human skin diseases.  Arch Dermatol Res 1996, 288(8):426-430.
7. Sugiura H, Ebise H, Tazawa T, Tanaka K, Sugiura Y, Uehara M, Kikuchi
K, Kimura T: Large-scale DNA microarray analysis of atopic
skin lesions shows overexpression of an epidermal differenti-
ation gene cluster in the alternative pathway and lack of pro-
tective gene expression in the cornified envelope.  Br J
Dermatol 2005, 152(1):146-149.
8. Bousquet J, Van Cauwenberge P, Khaltaev N: Allergic rhinitis and
its impact on asthma.  The Journal of allergy and clinical immunology
2001, 108(5 Suppl):S147-334.
9. Aas K, Belin L: Standardization of diagnostic work in allergy.
Int Arch Allergy Appl Immunol 1973, 45(1):57-60.
10. Stephens M, Smith NJ, Donnelly P: A new statistical method for
haplotype reconstruction from population data.  Am J Hum
Genet 2001, 68(4):978-989.
11. Barnes KC: Gene-environment and gene-gene interaction
studies in the molecular genetic analysis of asthma and
atopy.  Clin Exp Allergy 1999, 29 (Suppl 4):47-51.
12. Hoffjan S, Nicolae D, Ober C: Association studies for asthma
and atopic diseases: a comprehensive review of the litera-
ture.  Respir Res 2003, 4:14.
13. Ober C, Hoffjan S: Asthma genetics 2006: the long and winding
road to gene discovery.  Genes Immun 2006, 7(2):95-100.
14. Borglum AD, Flint T, Madsen P, Celis JE, Kruse TA: Refined map-
ping of the psoriasin gene S100A7 to chromosome 1cen-q21.
Hum Genet 1995, 96(5):592-596.
15. Schafer BW, Wicki R, Engelkamp D, Mattei MG, Heizmann CW: Iso-
lation of a YAC clone covering a cluster of nine S100 genes
on human chromosome 1q21: rationale for a new nomencla-
ture of the S100 calcium-binding protein family.  Genomics
1995, 25(3):638-643.
16. Marenholz I, Lovering RC, Heizmann CW: An update of the S100
nomenclature.  Biochimica et biophysica acta 2006,
1763(11):1282-1283.
17. Semprini S, Capon F, Bovolenta S, Bruscia E, Pizzuti A, Fabrizi G, Schi-
etroma C, Zambruno G, Dallapiccola B, Novelli G: Genomic struc-
ture, promoter characterisation and mutational analysis of
the S100A7 gene: exclusion of a candidate for familial psoria-
sis susceptibility.  Hum Genet 1999, 104(2):130-134.
18. Kruglyak L, Nickerson DA: Variation is the spice of life.  Nat Genet
2001, 27(3):234-236.
19. Brodersen DE, Etzerodt M, Madsen P, Celis JE, Thogersen HC,
Nyborg J, Kjeldgaard M: EF-hands at atomic resolution: the
structure of human psoriasin (S100A7) solved by MAD phas-
ing.  Structure 1998, 6(4):477-489.
20. Wolf R, Mirmohammadsadegh A, Walz M, Lysa B, Tartler U, Remus
R, Hengge U, Michel G, Ruzicka T: Molecular cloning and charac-
terization of alternatively spliced mRNA isoforms from pso-
riatic skin encoding a novel member of the S100 family.  Faseb
J 2003, 17(13):1969-1971.
21. Gaugris S, Sazonov-Kocevar V, Thomas M: Burden of concomitant
allergic rhinitis in adults with asthma.  J Asthma 2006, 43(1):1-7.
22. Leynaert B, Neukirch C, Kony S, Guenegou A, Bousquet J, Aubier M,
Neukirch F: Association between asthma and rhinitis accord-
ing to atopic sensitization in a population-based study.  The
Journal of allergy and clinical immunology 2004, 113(1):86-93.
23. Glaser R, Harder J, Lange H, Bartels J, Christophers E, Schroder JM:
Antimicrobial psoriasin (S100A7) protects human skin from
Escherichia coli infection.  Nat Immunol 2005, 6(1):57-64.
Additional file 1
Sequencing and genotyping primers for S100A7. Contains primer 
sequences for sequencing and genotyping of S100A7.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1465-
9921-9-29-S1.doc]